Phenotype of Gc-globulin influences the macrophage activating factor (MAF) levels in serum

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 11, 2011, Pages 1855-1860

  Debruyne, Evi ^a   Speeckaert, Marijn ^a   Weygaerde, Yannick Vande ^a   Delanghe, Joris ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Gc globulin; Gc MAF; Helix pomatia agglutinin; Lectin based ELISA; Phenotype; Tumour marker

Indexed keywords

MACROPHAGE ACTIVATING FACTOR; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BELGIUM; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPHENOTYPING; LECTINS; MACROPHAGE ACTIVATION; MACROPHAGE-ACTIVATING FACTORS; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; VITAMIN D-BINDING PROTEIN;

HELIX POMATIA;

EID: 80755168437     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.676     Document Type: Article

References (23)

1. Cleve H, Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox Sang 1988;54:215-25.
2. Parker WC, Cleve H, Bearn AG. Determination of phenotypes in the human group-specific component (Gc) system by starch gel electrophoresis. Am J Hum Genet 1963;15:353-67.
3. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372:33-42. (Pubitemid 44286753)
4. Yamamoto N, Homma S. Vitamin D3 binding protein (groupspecific component) is a precursor for the macrophageactivating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 1991;88:8539-43. (Pubitemid 21915392)
5. Van Baelen H, Bouillon R, De Moor P. Vitamin D-binding protein (Gc-globulin) binds actin. J Biol Chem 1980;255:2270-2. (Pubitemid 10036030)
6. Ena JM, Esteban C, Perez MD, Uriel J, Calvo M. Fatty acids bound to vitamin D-binding protein (DBP) from human and bovine sera. Biochem Int 1989;19:1-7. (Pubitemid 19190941)
7. Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol 1993;151:2794-802. (Pubitemid 23264531)
8. Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, et al. Gc protein (Vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res 2005;25: 3689-95. (Pubitemid 41658440)
9. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40. (Pubitemid 36151056)
10. Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010;5:e13428.
11. Dass CR, Nadesapillai AP, Robin D, Howard ML, Fisher JL, Zhou H, et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 2005;22: 643-52. (Pubitemid 44259525)
12. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, et al. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 2008;10:439-49. (Pubitemid 351657386)
13. Serratí S, Margheri F, Fibbi G, Di Cara G, Minafra L, Pucci- Minafra I, et al. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR- 4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression. J Pathol 2008;214: 545-54. (Pubitemid 351492460)
14. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122-36.
15. Yamamoto N, Naraparaju VR, Asbell SO. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res 1996;56:2827-31. (Pubitemid 26175743)
16. Yamamoto N, Naraparaju VR, Urade M. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 1997;57:295-9. (Pubitemid 27036609)
17. Kanan RM, Cook DB, Datta HK. Lectin immunoassay for macrophage-activating factor (Gc-MAF) produced by deglycosylation of Gc-globulin: evidence for noninducible generation of Gc-MAF. Clin Chem 2000;46:412-4. (Pubitemid 30152269)
18. Hammarstrom S, Kabat EA. Studies on specificity and binding properties of the blood group A reactive hemagglutinin from Helix pomatia. Biochemistry 1971;10:1684-92.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
20. Dunbar B. Protein blotting: a practical approach. Oxford: Oxford University Press, 1994.
21. Leray G, Guenet L, Le Treut A, Le Gall JY. Age-related decrease in lysosomal beta-D-galactosidase activity of human liver cell lines: argument against post-traductional modifications. Biochem Biophys Res Commun 1981;100:1491-6. (Pubitemid 11026046)
22. Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD. Physical activity and cancer prevention: pathways and targets for intervention. Sports Med 2008;38:271-96. (Pubitemid 351430296)
23. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet 1986;72:281-93. (Pubitemid 16087987)